[Angiotensin II antagonists: a promising pathway].
Cohen-Solal
A
A
Hôpital Beaujon, Clichy.
D000368:Aged; D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000502:physiology; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use; D002303:Cardiac Output, Low / Q000188:drug therapy*; D053818:Chymases; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D012697:Serine Endopeptidases / Q000502:physiology; D014665:Vasodilator Agents / Q000627:therapeutic use*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D014665:Vasodilator Agents; D000804:Angiotensin II; D002216:Captopril; D012697:Serine Endopeptidases; D053818:Chymases; D019808:Losartan